231 related articles for article (PubMed ID: 30632226)
1. Efficacy of progesterone on threatened miscarriage: Difference in drug types.
Wang XX; Luo Q; Bai WP
J Obstet Gynaecol Res; 2019 Apr; 45(4):794-802. PubMed ID: 30632226
[TBL] [Abstract][Full Text] [Related]
2. Supplementation with progestogens in the first trimester of pregnancy to prevent miscarriage in women with unexplained recurrent miscarriage: a systematic review and meta-analysis of randomized, controlled trials.
Saccone G; Schoen C; Franasiak JM; Scott RT; Berghella V
Fertil Steril; 2017 Feb; 107(2):430-438.e3. PubMed ID: 27887710
[TBL] [Abstract][Full Text] [Related]
3. The Influence of Oral Dydrogesterone and Vaginal Progesterone on Threatened Abortion: A Systematic Review and Meta-Analysis.
Lee HJ; Park TC; Kim JH; Norwitz E; Lee B
Biomed Res Int; 2017; 2017():3616875. PubMed ID: 29392134
[TBL] [Abstract][Full Text] [Related]
4. Effect of progestogen for women with threatened miscarriage: a systematic review and meta-analysis.
Li L; Zhang Y; Tan H; Bai Y; Fang F; Faramand A; Chong W; Hai Y
BJOG; 2020 Aug; 127(9):1055-1063. PubMed ID: 32324957
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of progesterone on threatened miscarriage: an updated meta-analysis of randomized trials.
Yan Y; Chen Z; Yang Y; Zheng X; Zou M; Cheng G; Yuan Z
Arch Gynecol Obstet; 2021 Jan; 303(1):27-36. PubMed ID: 32989508
[TBL] [Abstract][Full Text] [Related]
6. Oral dydrogesterone for prevention of miscarriage in threatened miscarriage: a randomized, double-blind, placebo-controlled trial.
Kuptarak A; Phupong V
J Matern Fetal Neonatal Med; 2024 Dec; 37(1):2333929. PubMed ID: 38570191
[TBL] [Abstract][Full Text] [Related]
7. A randomized double-blind controlled trial of the use of dydrogesterone in women with threatened miscarriage in the first trimester: study protocol for a randomized controlled trial.
Chan DM; Cheung KW; Yung SS; Lee VC; Li RH; Ng EH
Trials; 2016 Aug; 17(1):408. PubMed ID: 27534747
[TBL] [Abstract][Full Text] [Related]
8. Progestogen for treating threatened miscarriage.
Wahabi HA; Abed Althagafi NF; Elawad M
Cochrane Database Syst Rev; 2007 Jul; (3):CD005943. PubMed ID: 17636813
[TBL] [Abstract][Full Text] [Related]
9. The randomised controlled trial of micronised progesterone and dydrogesterone (TRoMaD) for threatened miscarriage.
Siew JYS; Allen JC; Hui CYY; Ku CW; Malhotra R; Østbye T; Tan TC
Eur J Obstet Gynecol Reprod Biol; 2018 Sep; 228():319-324. PubMed ID: 30077119
[TBL] [Abstract][Full Text] [Related]
10. A systematic review of dydrogesterone for the treatment of threatened miscarriage.
Carp H
Gynecol Endocrinol; 2012 Dec; 28(12):983-90. PubMed ID: 22794306
[TBL] [Abstract][Full Text] [Related]
11. Real-world pharmacological treatment patterns of patients with threatened miscarriage in China from 2014 to 2020: A cross-sectional analysis.
Pang YY; Ma CL
J Clin Pharm Ther; 2022 Feb; 47(2):228-236. PubMed ID: 34704273
[TBL] [Abstract][Full Text] [Related]
12. Physiology should be supported with evidence in progesterone administration for threatened miscarriage.
Sotiriadis A; Makrydimas G
Am J Reprod Immunol; 2005 Oct; 54(4):240. PubMed ID: 16135015
[No Abstract] [Full Text] [Related]
13. A pairwise and network meta-analysis comparing the efficacy and safety of progestogens in threatened abortion.
Zhao H; He W; Yang Z
Int J Gynaecol Obstet; 2022 Mar; 156(3):383-393. PubMed ID: 33864694
[TBL] [Abstract][Full Text] [Related]
14. Progestogen for treating threatened miscarriage.
Wahabi HA; Fayed AA; Esmaeil SA; Al Zeidan RA
Cochrane Database Syst Rev; 2011 Dec; (12):CD005943. PubMed ID: 22161393
[TBL] [Abstract][Full Text] [Related]
15. Dydrogesterone in threatened abortion: pregnancy outcome.
Omar MH; Mashita MK; Lim PS; Jamil MA
J Steroid Biochem Mol Biol; 2005 Dec; 97(5):421-5. PubMed ID: 16293412
[TBL] [Abstract][Full Text] [Related]
16. Micronized vaginal progesterone to prevent miscarriage: a critical evaluation of randomized evidence.
Coomarasamy A; Devall AJ; Brosens JJ; Quenby S; Stephenson MD; Sierra S; Christiansen OB; Small R; Brewin J; Roberts TE; Dhillon-Smith R; Harb H; Noordali H; Papadopoulou A; Eapen A; Prior M; Di Renzo GC; Hinshaw K; Mol BW; Lumsden MA; Khalaf Y; Shennan A; Goddijn M; van Wely M; Al-Memar M; Bennett P; Bourne T; Rai R; Regan L; Gallos ID
Am J Obstet Gynecol; 2020 Aug; 223(2):167-176. PubMed ID: 32008730
[TBL] [Abstract][Full Text] [Related]
17. Dydrogesterone vs progesterone for luteal-phase support: systematic review and meta-analysis of randomized controlled trials.
Barbosa MW; Silva LR; Navarro PA; Ferriani RA; Nastri CO; Martins WP
Ultrasound Obstet Gynecol; 2016 Aug; 48(2):161-70. PubMed ID: 26577241
[TBL] [Abstract][Full Text] [Related]
18. Use of oral progestogen in women with threatened miscarriage in the first trimester: a randomized double-blind controlled trial.
Chan DMK; Cheung KW; Ko JKY; Yung SSF; Lai SF; Lam MT; Ng DYT; Lee VCY; Li RHW; Ng EHY
Hum Reprod; 2021 Feb; 36(3):587-595. PubMed ID: 33331637
[TBL] [Abstract][Full Text] [Related]
19. Progestogen for treating threatened miscarriage.
Wahabi HA; Abed Althagafi NF; Elawad M; Al Zeidan RA
Cochrane Database Syst Rev; 2011 Mar; (3):CD005943. PubMed ID: 21412891
[TBL] [Abstract][Full Text] [Related]
20. Treatment options for threatened miscarriage.
Qureshi NS
Maturitas; 2009 Dec; 65 Suppl 1():S35-41. PubMed ID: 19945236
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
